A phase 3 clinical trial of the liquid-frozen formulation of the Imvamune smallpox vaccine and a phase 2 trial of a freeze-dried version of the agent have demonstrated positive outcomes, according to a press release from manufacturer Bavarian Nordic.
The phase 3 trial included 4,000 participants; 3,000 received one of three unique manufacturing lots of the liquid-frozen formulation, and 1,000 participants were assigned placebo vaccine. Those who received liquid-frozen Imvamune demonstrated equivalent antibody responses between lots, with no serious adverse events reported.
- Disorders & Diseases
- Public Health
- Products & Treatment
- Department Management